Key Takeaways
- • Baker Brothers Advisors, founded in 2000 by brothers Julian and Felix Baker, ranks as the 15th-largest U.S. hedge fund through 2022 with elite institutional clients including Yale University's endowment and the Tisch family, despite operating as a deliberately secretive operation with no website and no media engagement.
- • The biotech-focused hedge fund held 115 stock positions as of end-2022, with cancer therapy company Seagen as its largest investment valued at approximately $6 billion, up roughly 500% since initial acquisition in the early 2000s, generating among the fund's most profitable returns.
- • Incyte Corporation, a multinational biopharmaceutical company, represented the fund's second-largest position with a market value of $2.9 billion at end-2022, reflecting the fund's concentrated conviction in high-conviction biotech bets.
- • The Baker brothers, now in their 50s, leverage immunology-related academic backgrounds to specialize in biotech sector investing, beginning their investment management relationship with the Tisch family's healthcare portfolio in 1994 and managing Yale endowment capital through the 667 LP vehicle since at least 2009.
- • Baker Brothers maintains a relatively low portfolio turnover rate despite managing substantial assets, indicating a long-term, buy-and-hold investment philosophy centered on sustained conviction positions within the biotechnology and healthcare sectors.
Summary
Baker Brothers Advisors operates as one of the most secretive yet successful biotech-focused hedge funds in the United States, managing capital for some of the country's most prominent institutional investors. The New York-based firm, established in 2000 by brothers Julian and Felix Baker, has grown to rank 15th among U.S. hedge funds as of 2022, despite the founders' deliberate avoidance of media attention and the absence of a public website. The fund's limited public profile contrasts sharply with its outsized influence and track record, having attracted elite clients including Yale University's endowment and the Tisch family early in its operational history.
The Baker brothers bring specialized expertise to their investment approach, leveraging academic backgrounds in immunology to identify opportunities within the biotech sector during its decade of substantial expansion. Their relationship with institutional capital spans decades: the brothers began managing the Tisch family's healthcare investments in 1994, while Yale's philanthropic foundation has maintained an investment in the Baker Bros. vehicle known as 667 LP since at least 2009. The founders' success has been substantial—Julian Baker's personal net worth has reached $2.6 billion according to Forbes—yet both brothers have maintained complete opacity regarding their investment philosophy and operational approach.
As of the fourth quarter of 2022, Baker Brothers Advisors managed a healthcare-focused hedge fund with 115 stock holdings, characterized by concentrated conviction positions and notably low portfolio turnover. Seagen, a cancer therapeutics company, anchored the portfolio as the largest investment with an approximate $6 billion position. The fund's acquisition of Seagen in the early 2000s has proven among its most lucrative investments, with the equity generating approximately 500% returns over the past decade. Incyte Corporation, a multinational biopharmaceutical enterprise, represented the second-largest holding at $2.9 billion in market value, further underscoring the fund's strategic focus on deriving outsized returns from carefully selected biotech opportunities.
The Baker brothers bring specialized expertise to their investment approach, leveraging academic backgrounds in immunology to identify opportunities within the biotech sector during its decade of substantial expansion. Their relationship with institutional capital spans decades: the brothers began managing the Tisch family's healthcare investments in 1994, while Yale's philanthropic foundation has maintained an investment in the Baker Bros. vehicle known as 667 LP since at least 2009. The founders' success has been substantial—Julian Baker's personal net worth has reached $2.6 billion according to Forbes—yet both brothers have maintained complete opacity regarding their investment philosophy and operational approach.
As of the fourth quarter of 2022, Baker Brothers Advisors managed a healthcare-focused hedge fund with 115 stock holdings, characterized by concentrated conviction positions and notably low portfolio turnover. Seagen, a cancer therapeutics company, anchored the portfolio as the largest investment with an approximate $6 billion position. The fund's acquisition of Seagen in the early 2000s has proven among its most lucrative investments, with the equity generating approximately 500% returns over the past decade. Incyte Corporation, a multinational biopharmaceutical enterprise, represented the second-largest holding at $2.9 billion in market value, further underscoring the fund's strategic focus on deriving outsized returns from carefully selected biotech opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.